Trial Outcomes & Findings for Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies (NCT NCT04181788)

Last Updated: 2026-04-27

Results Overview

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with first line (1L) and second line (2L) non-small cell lung cancer (NSCLC) (Phase 2). For the Phase 1b, any of the following AEs occurring during the DLT observation period (the first cycle of treatment) which were attributable to the investigational product were classified as DLTs: Grade 5 AE not clearly due to the underlying disease or extraneous causes; Hematologic toxicity; Non-Hematologic Toxicity; Delay of ≥ 3 weeks in receiving the next scheduled administration due to persisting treatment-related toxicities.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE1/PHASE2

Target enrollment

155 participants

Primary outcome timeframe

Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms

Results posted on

2026-04-27

Participant Flow

Participant milestones

Participant milestones
Measure	Phase 1b Escalation 300 mg SC Q4W PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 300 mg SC Q4W PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20.	Phase 1b Escalation 600 mg SC Q6W PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 600 mg SC Q6W PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8.	Phase 2 300 mg SC Q4W PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28.	Phase 2 600 mg SC Q6W PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18.
TREATMENT STARTED	4	12	6	12	41	80
TREATMENT COMPLETED	0	0	0	0	0	0
TREATMENT NOT COMPLETED	4	12	6	12	41	80
FOLLOW-UP STARTED	3	9	6	7	20	49
FOLLOW-UP COMPLETED	3	8	4	2	9	22
FOLLOW-UP NOT COMPLETED	0	1	2	5	11	27

Reasons for withdrawal

Reasons for withdrawal
Measure	Phase 1b Escalation 300 mg SC Q4W PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 300 mg SC Q4W PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20.	Phase 1b Escalation 600 mg SC Q6W PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 600 mg SC Q6W PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8.	Phase 2 300 mg SC Q4W PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28.	Phase 2 600 mg SC Q6W PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18.
TREATMENT Withdrawal by Subject	1	2	0	0	3	5
TREATMENT Other unspecified	0	0	0	0	0	2
TREATMENT Ongoing	0	3	0	5	7	15
FOLLOW-UP Death	0	0	1	2	8	20
FOLLOW-UP Lost to Follow-up	0	0	0	0	0	2
FOLLOW-UP Withdrawal by Subject	0	0	0	0	1	0
FOLLOW-UP Other unspecified	0	1	0	0	0	3
FOLLOW-UP Ongoing	0	0	1	3	2	2
TREATMENT Adverse Event	0	2	1	0	1	3
TREATMENT Death	0	0	0	0	8	8
TREATMENT Physician Decision	0	0	0	0	0	1
TREATMENT Progressive disease	3	3	5	7	20	38
TREATMENT Global deterioration of health status	0	2	0	0	2	8

Baseline Characteristics

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Phase 1b Expansion 300 mg SC Q4W n=12 Participants PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20.	Phase 1b Escalation 600 mg SC Q6W n=6 Participants PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 600 mg SC Q6W n=12 Participants PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8.	Phase 2 300 mg SC Q4W n=41 Participants PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28.	Phase 2 600 mg SC Q6W n=80 Participants PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18.	Total n=155 Participants Total of all reporting groups	Phase 1b Escalation 300 mg SC Q4W n=4 Participants PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9.
Age, Customized 65 - <75 years	5 Participants n=240 Participants	1 Participants n=236 Participants	4 Participants n=702 Participants	17 Participants n=211 Participants	21 Participants n=76 Participants	49 Participants n=401 Participants	1 Participants n=226 Participants
Age, Continuous	57.3 Years STANDARD_DEVIATION 15.78 • n=240 Participants	62.7 Years STANDARD_DEVIATION 10.33 • n=236 Participants	62.4 Years STANDARD_DEVIATION 10.02 • n=702 Participants	63.9 Years STANDARD_DEVIATION 11.75 • n=211 Participants	62.9 Years STANDARD_DEVIATION 10.62 • n=76 Participants	62.6 Years STANDARD_DEVIATION 11.33 • n=401 Participants	62.0 Years STANDARD_DEVIATION 13.29 • n=226 Participants
Age, Customized <65 years	7 Participants n=240 Participants	4 Participants n=236 Participants	6 Participants n=702 Participants	18 Participants n=211 Participants	48 Participants n=76 Participants	85 Participants n=401 Participants	2 Participants n=226 Participants
Age, Customized 75 - <85 years	0 Participants n=240 Participants	1 Participants n=236 Participants	2 Participants n=702 Participants	5 Participants n=211 Participants	10 Participants n=76 Participants	19 Participants n=401 Participants	1 Participants n=226 Participants
Age, Customized ≥85 years	0 Participants n=240 Participants	0 Participants n=236 Participants	0 Participants n=702 Participants	1 Participants n=211 Participants	1 Participants n=76 Participants	2 Participants n=401 Participants	0 Participants n=226 Participants
Sex: Female, Male Female	6 Participants n=240 Participants	3 Participants n=236 Participants	3 Participants n=702 Participants	9 Participants n=211 Participants	14 Participants n=76 Participants	39 Participants n=401 Participants	4 Participants n=226 Participants
Sex: Female, Male Male	6 Participants n=240 Participants	3 Participants n=236 Participants	9 Participants n=702 Participants	32 Participants n=211 Participants	66 Participants n=76 Participants	116 Participants n=401 Participants	0 Participants n=226 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=240 Participants	0 Participants n=236 Participants	0 Participants n=702 Participants	0 Participants n=211 Participants	0 Participants n=76 Participants	0 Participants n=401 Participants	0 Participants n=226 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	12 Participants n=240 Participants	6 Participants n=236 Participants	12 Participants n=702 Participants	41 Participants n=211 Participants	80 Participants n=76 Participants	155 Participants n=401 Participants	4 Participants n=226 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=240 Participants	0 Participants n=236 Participants	0 Participants n=702 Participants	0 Participants n=211 Participants	0 Participants n=76 Participants	0 Participants n=401 Participants	0 Participants n=226 Participants
Race/Ethnicity, Customized White	0 Participants n=240 Participants	0 Participants n=236 Participants	0 Participants n=702 Participants	34 Participants n=211 Participants	62 Participants n=76 Participants	96 Participants n=401 Participants	0 Participants n=226 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=240 Participants	0 Participants n=236 Participants	0 Participants n=702 Participants	0 Participants n=211 Participants	0 Participants n=76 Participants	0 Participants n=401 Participants	0 Participants n=226 Participants
Race/Ethnicity, Customized Asian	12 Participants n=240 Participants	6 Participants n=236 Participants	12 Participants n=702 Participants	7 Participants n=211 Participants	18 Participants n=76 Participants	59 Participants n=401 Participants	4 Participants n=226 Participants
Race/Ethnicity, Customized Multiracial	0 Participants n=240 Participants	0 Participants n=236 Participants	0 Participants n=702 Participants	0 Participants n=211 Participants	0 Participants n=76 Participants	0 Participants n=401 Participants	0 Participants n=226 Participants
Race/Ethnicity, Customized Not Reported	0 Participants n=240 Participants	0 Participants n=236 Participants	0 Participants n=702 Participants	0 Participants n=211 Participants	0 Participants n=76 Participants	0 Participants n=401 Participants	0 Participants n=226 Participants

PRIMARY outcome

Timeframe: Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms

Population: DLT-evaluable analysis set included all participants who received at least 1 dose of study treatment in the Phase 1b and either experienced DLT during the DLT-evaluation period or completed the DLT-evaluation period without DLT.

Outcome measures

Outcome measures
Measure	Phase 1b Escalation 300 mg SC Q4W n=3 Participants PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 300 mg SC Q4W n=11 Participants PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20.	Phase 1b Escalation 600 mg SC Q6W n=6 Participants PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 600 mg SC Q6W n=12 Participants PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8.
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm

Population: Phase 2: The PK concentration analysis set was a subset of the safety analysis set and included participants who had at least 1 reportable concentration measurement. Safety analysis set included all enrolled participants who received at least 1 dose of study drug. Here "Number of participants analyzed" signifies participants who had data available for this outcome measure.

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (at steady state, starting at Week 12). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)

Outcome measures

Outcome measures
Measure	Phase 1b Escalation 300 mg SC Q4W n=23 Participants PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 300 mg SC Q4W n=49 Participants PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20.	Phase 1b Escalation 600 mg SC Q6W PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 600 mg SC Q6W PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8.
Phase 2: AUCτ of PF-06801591 at Steady State	20800 microgramhour per milliliter (μghr/mL) Geometric Coefficient of Variation 54	48090 microgramhour per milliliter (μghr/mL) Geometric Coefficient of Variation 47	—	—

PRIMARY outcome

Timeframe: Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Steady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)

Outcome measures

Outcome measures
Measure	Phase 1b Escalation 300 mg SC Q4W n=24 Participants PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 300 mg SC Q4W n=55 Participants PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20.	Phase 1b Escalation 600 mg SC Q6W PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 600 mg SC Q6W PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8.
Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12	21.48 microgram per milliliter (μg/mL) Geometric Coefficient of Variation 60	23.95 microgram per milliliter (μg/mL) Geometric Coefficient of Variation 74	—	—

SECONDARY outcome

Timeframe: Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day).

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Outcome measures

Outcome data not reported

SECONDARY outcome

Laboratory results were classified according to the NCI-CTCAE criteria version 5.0. Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care (ADL); Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Number of participants with Grade 1 to Grade 4 laboratory abnormalities were reported.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Cycle 1 Day 1, 8, 15, 22, Cycle 2 Day 1; for the PF-06801591 600 mg SC Q6W arms, Cycle 1 Day 1, 8, 15, 29, Cycle 2 Day 1

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (after single dose). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Phase 1b/2: Cycle 2 Day 1 for all Arms

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Ctrough is pre-dose concentration after single dose (first dose).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Day 1 of Cycle 4; for the PF-06801591 600 mg SC Q6W arms, Day 1 of Cycle 3

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Phase 1b/2: Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10 and end of treatment (EOT) for the PF-06801591 300 mg SC Q4W arms; Day 1 of Cycle 1, 2, 3, 4, 5, 7 and EOT for the PF-06801591 600 mg SC Q6W arms

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Treatment-induced ADA = Baseline ADA titer was missing or negative and participant had ≥1 post-treatment positive ADA titer (ADA titer greater than or equal to 99 with assay cut-point of 1.09). Treatment-induced NAb = Baseline NAb titer was missing or negative or ADA-negative and participant had ≥1 post-treatment positive NAb titer.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Phase 1b/2: Up to 30 months

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST v1.1. Complete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. Partial Response (PR): Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Phase 1b/2: Up to 30 months

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). TTR was defined for participants with confirmed objective response (CR or PR) as the time from the 'start date' to the date of first documentation of objective tumor response which is subsequently confirmed.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Phase 1b/2: Baseline up to 30 months

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed BOR of CR or PR according to RECIST v1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. PR: Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and inflammatory cells in regions of interest that are defined by tumor cell morphology.

Outcome measures

Outcome data not reported

Adverse Events

Phase 1b Escalation 300 mg SC Q4W

Serious events: 1 serious events

Other events: 4 other events

Deaths: 0 deaths

Phase 1b Expansion 300 mg SC Q4W

Serious events: 2 serious events

Other events: 11 other events

Deaths: 0 deaths

Phase 1b Escalation 600 mg SC Q6W

Serious events: 0 serious events

Other events: 6 other events

Deaths: 1 deaths

Phase 1b Expansion 600 mg SC Q6W

Serious events: 0 serious events

Other events: 12 other events

Deaths: 2 deaths

Phase 2 300 mg SC Q4W

Serious events: 16 serious events

Other events: 40 other events

Deaths: 16 deaths

Phase 2 600 mg SC Q6W

Serious events: 13 serious events

Other events: 58 other events

Deaths: 31 deaths

Serious adverse events

Serious adverse events
Measure	Phase 1b Escalation 300 mg SC Q4W n=4 participants at risk PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 300 mg SC Q4W n=12 participants at risk PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20.	Phase 1b Escalation 600 mg SC Q6W n=6 participants at risk PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 600 mg SC Q6W n=12 participants at risk PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8.	Phase 2 300 mg SC Q4W n=41 participants at risk PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28.	Phase 2 600 mg SC Q6W n=80 participants at risk PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18.
Blood and lymphatic system disorders Anaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Cardiac disorders Pericardial effusion	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Cardiac disorders Ventricular extrasystoles	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Ear and labyrinth disorders Vertigo	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Endocrine disorders Inappropriate antidiuretic	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Disease progression	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	9.8% 4/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Hepatobiliary disorders Immune-mediated hepatitis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations COVID-19	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations COVID-19 pneumonia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Cellulitis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Herpes zoster	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Pneumonia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Pneumonia viral	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Sepsis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Septic shock	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Injury, poisoning and procedural complications Femur fracture	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Electrocardiogram QT prolonged	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Transaminases increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Renal and urinary disorders Tubulointerstitial nephritis	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Drug eruption	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Vascular disorders Hypotension	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.

Other adverse events

Other adverse events
Measure	Phase 1b Escalation 300 mg SC Q4W n=4 participants at risk PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 300 mg SC Q4W n=12 participants at risk PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20.	Phase 1b Escalation 600 mg SC Q6W n=6 participants at risk PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9.	Phase 1b Expansion 600 mg SC Q6W n=12 participants at risk PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8.	Phase 2 300 mg SC Q4W n=41 participants at risk PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28.	Phase 2 600 mg SC Q6W n=80 participants at risk PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18.
Blood and lymphatic system disorders Anaemia	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	33.3% 4/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	50.0% 6/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	19.5% 8/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	12.5% 10/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Blood and lymphatic system disorders Leukopenia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Cardiac disorders Arrhythmia supraventricular	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Cardiac disorders Atrioventricular block first degree	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Cardiac disorders Sinus bradycardia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Cardiac disorders Sinus tachycardia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	9.8% 4/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Cardiac disorders Supraventricular extrasystoles	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Cardiac disorders Ventricular extrasystoles	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Endocrine disorders Hyperthyroidism	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Endocrine disorders Hypothyroidism	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	6.2% 5/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Eye disorders Vision blurred	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	9.8% 4/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Abdominal pain	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Chronic gastritis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Diarrhoea	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	7.3% 3/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Nausea	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Toothache	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Gastrointestinal disorders Vomiting	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Asthenia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	22.0% 9/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	7.5% 6/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Chest pain	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	12.2% 5/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Fatigue	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	12.2% 5/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Hyperthermia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	9.8% 4/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Injection site reaction	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Malaise	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Oedema	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Oedema peripheral	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Pain	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Peripheral swelling	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	7.3% 3/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Pyrexia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	9.8% 4/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	5.0% 4/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
General disorders Swelling	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Bronchitis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Conjunctivitis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Herpes zoster	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Pneumonia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Respiratory tract infection viral	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	6.2% 5/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Skin infection	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Upper respiratory tract infection	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Infections and infestations Urinary tract infection	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Alanine aminotransferase increased	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	25.0% 3/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	12.2% 5/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	7.5% 6/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Amylase increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Aspartate aminotransferase increased	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	9.8% 4/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Bilirubin conjugated increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood alkaline phosphatase increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood bilirubin increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	25.0% 3/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood corticotrophin decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood corticotrophin increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood creatine phosphokinase increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood creatinine increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood glucose decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood glucose increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	33.3% 4/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood sodium decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood thyroid stimulating hormone decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood thyroid stimulating hormone increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Blood urea increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Cortisol decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Free thyroxine index increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Gamma-glutamyltransferase increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Lipase increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	6.2% 5/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Lymphocyte count decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Neutrophil count decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	25.0% 3/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Neutrophil count increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Red blood cell count increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Thyroid hormones decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Total bile acids increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Weight decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	19.5% 8/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	12.5% 10/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations Weight increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations White blood cell count decreased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Investigations White blood cell count increased	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	19.5% 8/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	10.0% 8/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hypermagnesaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hyperphosphataemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	33.3% 4/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	25.0% 3/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	33.3% 4/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	25.0% 3/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	25.0% 3/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hypochloraemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	33.3% 4/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	12.2% 5/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	6.2% 5/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	7.3% 3/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Musculoskeletal and connective tissue disorders Gouty arthritis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.5% 2/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	9.8% 4/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	1.2% 1/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Nervous system disorders Cerebral ischaemia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Nervous system disorders Dizziness	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	7.3% 3/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Nervous system disorders Headache	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	7.3% 3/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.8% 7/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Nervous system disorders Hypoaesthesia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Psychiatric disorders Insomnia	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	4.9% 2/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Renal and urinary disorders Proteinuria	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Atelectasis	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	14.6% 6/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	22.0% 9/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	13.8% 11/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	9.8% 4/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	3.8% 3/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Hydrothorax	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	12.2% 5/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	5.0% 4/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Pruritus	25.0% 1/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	25.0% 3/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	50.0% 3/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 2/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	7.5% 6/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Rash	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	25.0% 3/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	25.0% 3/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	5.0% 4/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	2.4% 1/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Skin disorder	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	16.7% 1/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Skin exfoliation	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Skin hypopigmentation	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.
Skin and subcutaneous tissue disorders Vitiligo	0.00% 0/4 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	8.3% 1/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/6 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/12 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/41 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.	0.00% 0/80 • Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality. Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER